Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

The phase 3 LEONARDA-1 trial evaluated the efficacy and safety of lerociclib in patients with locally advanced HR+ HER2- breast cancer who had disease recurrence or progression on prior endocrine therapy. Data from 275 patients showed that patients in the lerociclib plus fulvestrant arm had significantly improved progression-free survival compared with patients in the placebo plus fulvestrant arm.